What's in Alnylam Pharmaceuticals, Inc.'s pipeline?

Alnylam Pharmaceuticals, Inc. has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Alnylam Pharmaceuticals, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alnylam.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Alnylam Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Alnylam Pharmaceuticals, Inc. (ALNY) pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ALNY (NASDAQ) 5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amvuttra	VUTRISIRAN	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	Neuroscience	2022-01-01
Oxlumo	LUMASIRAN	marketed		Hydroxyacid oxidase 1 (HAO1) mRNA	Metabolic	2020-01-01
Givlaari	GIVOSIRAN	marketed	Aminolevulinate Synthase 1-directed RNA Interaction	aminolevulinate synthase1 (ALAS1) mRNA	Neuroscience	2019-01-01
Onpattro	PATISIRAN	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	Neuroscience	2018-01-01
Onpattro	PATISIRAN SODIUM	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	Neuroscience	2018-01-01

Therapeutic area mix

Neuroscience · 4
Metabolic · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Alnylam Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Alnylam Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alnylam. Accessed 2026-05-15.